Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01062555 · ClinicalTrials.gov registry record · Phase 1
Calcineurin Inhibitor Sparing After Kidney Transplantation
A Phase 1 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 527
- Enrollment target
NCT01062555 is a Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 527 participants.
The verdict
NCT01062555, a Phase 1 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 527 participants
- Enrollment target
Study Summary
Reducing drug side effects is a key issue in transplantation. One class of drugs commonly used, calcineurin inhibitors (CNIs), is associated with negative side effects, namely, toxicity to the transplanted kidney. In some patients, this toxicity is thought to be associated with loss of transplant function in those who have had their transplants for many years. The introduction of new immunosuppression medications however, has provided the opportunity to minimize or avoid CNIs, which may reduce the occurrence of toxicity to the kidney.
Interventions
- DRUG Cyclosporine & Cellcept
- DRUG Prograf & Cellcept
- DRUG Low Dose CNI (Cyclosporine or FK) and Cellcept
- DRUG Rapamune and Cellcept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 527 participants |
| Start Date | 2006-10-01 |
| Est. Completion | 2014-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01062555
The ClinicalTrials.gov registry entry for NCT01062555 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 527 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclosporine & Cellcept is the first listed.
NCT01062555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01062555 about?
NCT01062555 is a clinical study titled "Calcineurin Inhibitor Sparing After Kidney Transplantation". Reducing drug side effects is a key issue in transplantation. One class of drugs commonly used, calcineurin inhibitors (CNIs), is associated with negative side effects, namely, toxicity to the transplanted kidney. In some patients, this toxicity is thought to be associated with loss of transplant fu...
What is the current status of trial NCT01062555?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 527 participants. The study started on 2006-10-01. Estimated completion is 2014-04-03.
What interventions are being tested in trial NCT01062555?
The interventions under investigation include: Cyclosporine & Cellcept (DRUG), Prograf & Cellcept (DRUG), Low Dose CNI (Cyclosporine or FK) and Cellcept (DRUG), Rapamune and Cellcept (DRUG).
Who is sponsoring clinical trial NCT01062555?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.